Effect of Xuanfuhua decoction on a mouse model of nonalcoholic steatohepatitis induced by high-fat, high-fructose, and high-cholesterol diet

Yijing XIN; Yiyun CHEN; Hailin YANG; Yunhui ZHUO; Dingqi ZHANG; Fengfeng ZHOU

doi:10.3969/j.issn.1001-5256.2023.06.014

Volume 39 Issue 6

Jun. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(6): 1340-1350

PDF( 4624 KB)

Effect of Xuanfuhua decoction on a mouse model of nonalcoholic steatohepatitis induced by high-fat, high-fructose, and high-cholesterol diet

DOI: 10.3969/j.issn.1001-5256.2023.06.014

Yijing XIN^1a,
Yiyun CHEN²,
Hailin YANG^1b,
Yunhui ZHUO^1a,
Dingqi ZHANG^{1b, 3
,
,
,},
Fengfeng ZHOU^{1a
,
,
,}

1a.
Department of Hepatology, Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
1b.
Institute of Liver Diseases, Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2.
Department of Traditional Chinese Medicine, Shanghai Pudong New Area Gongli Hospital, Shanghai 200120, China
3.
School of Pharmaceutical Sciences, School of TCM Research, Tsinghua University, Beijing 100084, China

Research funding:

Science and Technology Support Project of Shanghai Science and Technology Commission (19401934100);

Science and Technology Plan Project of Shanghai Science and Technology Commission (22Y11921000)

More Information

Corresponding author: ZHANG Dingqi, zhangdq1230@sina.com (ORCID: 0000-0002-5123-8188); ZHOU Fengfeng, yanchengzhou1@163.com (ORCID: 0000-0001-5677-4249)
Received Date: 2022-10-23
Accepted Date: 2022-11-25
Published Date: 2023-06-20

Abstract

Abstract

Objective To investigate the intervention effect of Xuanfuhua decoction on mice with nonalcoholic steatohepatitis (NASH) induced by high-fat, high-fructose, and high-cholesterol diet. Methods A total of 32 male C57/BL6J mice were randomly divided into normal group, model group, Xuanfuhua decoction group, and obeticholic acid group, with 8 mice in each group. Since week 24 of modeling using high-fat, high-fructose, and high-cholesterol diet, each group was given the corresponding drug for intervention at a dose of 14.19 g/kg by gavage for the Xuanfuhua decoction group and 10 mg/kg by gavage for the obeticholic acid group and a volume of 20 mL/kg for gavage, once a day for 6 consecutive weeks. HE staining, oil red O staining, Sirius Red staining, and Masson staining were used to observe the pathological changes, lipid deposition, and collagen deposition of liver tissue; related kits were used to measure the serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and glucose, as well as the content of TG and hydroxyproline (Hyp) in liver tissue; quantitative real-time PCR was used to measure the expression of genes associated with lipid metabolism, inflammation, and fibrosis in liver tissue; immunohistochemical staining was used to observe the positive expression of F4/80 and α-SMA in liver tissue. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups. Results Compared with the normal group, the model group had significant increases in body weight, liver wet weight, and serum levels of AST, ALT, TC, TG, LDL-C and glucose (all P < 0.01). HE staining showed hepatocyte steatosis, a large number of fat vacuoles, hepatocyte ballooning degeneration, and inflammatory cell infiltration in liver tissue of the mice in the model group, and the model group had a significant increase in NAFLD activity score (NAS) compared with the normal group (P < 0.01). Oil red O staining showed the deposition of a large number of red lipid droplets with different sizes in hepatocytes of the mice in the model group, and compared with the normal group, the model group had significant increases in the area percentage of oil red O staining and the content of TG in the liver (P < 0.01). Sirius Red staining and Masson staining showed significant collagen fiber hyperplasia in the perisinusoidal area, the central vein, and the portal area in the model group, and the model group had a significant increase in the content of Hyp in liver tissue compared with the normal group (P < 0.05). Compared with the model group, the Xuanfuhua decoction group had significant reductions in the serum levels of AST, ALT, TC, TG, LDL-C, and glucose (all P < 0.05), significant improvements in hepatic steatosis, inflammatory infiltration, lipid droplet deposition, and collagen fiber hyperplasia, and significant reductions in NAS score, area percentage of oil red O staining, and content of TG and Hyp in the liver (all P < 0.05). Compared with the normal group, the model group had significant increases in the mRNA expression levels of lipid metabolism-related genes (SREBP-1c, FASN, SCD-1, PPAR-γ, and CD36), inflammation-related genes (F4/80, TNF-α, CCL2, and CD11b), and the fibrosis-related gene α-SMA (all P < 0.05), and immunohistochemical staining showed significant increases in the positive expression of F4/80 and α-SMA (P < 0.01). Compared with the model group, the Xuanfuhua decoction group had significant reductions in the mRNA expression levels of SREBP-1c, FASN, SCD-1, PPAR-γ, CD36, F4/80, TNF-α, CCL2, CD11b, and α-SMA in liver tissue (all P < 0.05), and immunohistochemical staining showed significant reductions in the positive expression of F4/80 and α-SMA (P < 0.01). Conclusion Xuanfuhua decoction has a good intervention effect on mice with NASH induced by high fat, high fructose, and high-cholesterol diet and can significantly inhibit hepatic lipid deposition, inflammatory response, and liver fibrosis.
- Non-alcoholic Steatohepatitis,
- Xuanfuhua Decoction,
- Mice, Inbred C57BL

FullText(HTML)

肝移植是治疗终末期肝病的最终手段，成功的肝移植将延长患者生存期。但由于肝移植受者术前普遍基础条件差，且手术过程复杂，导致术后并发症复杂多样，从而影响术后效果。目前，国内鲜有直接预测肝移植受者术后早期并发症发生的相关研究。研究^[1-3]发现，肌肉减少症与肝移植术后并发症相关，腰大肌厚度/身高值(psoas muscle thickness per height，PMTH)可以通过脐平面的腰大肌横向厚度与患者的身高比值来诊断肌肉减少症，其计算方法简便，可用于预测肝移植等待名单中的患者死亡率^[4]。控制营养状态(controlling nutritional status，CONUT)评分是一种评估患者术前营养状态的工具，其由血清白蛋白、血清总胆固醇、总淋巴细胞计数计算得出^[5]。研究^[6-8]表明，CONUT评分与原发性肝癌(以下简称为肝癌)肝切除患者的预后相关。本文旨在通过肝移植受者术前PMTH、CONUT评分结合术前、术中相关危险因素建立肝移植术后早期并发症发生的风险预测模型，用于指导肝移植围手术期治疗。

1. 资料与方法

1.1 研究对象

回顾性收集2016年1月—2018年12月于天津市第一中心医院肝移植科接受原位肝移植患者的临床资料。纳入标准：(1)受者年龄18~65岁；(2)供者为公民逝世后器官捐献；(3)肝癌肝移植受者符合米兰标准；(4) 受者术前2个月内行腹部CT检查；(5)受者术前1周内行血清总胆固醇检查。排除标准：(1)2次、多次或者挽救性肝移植受者；(2)术前合并严重肺炎受者；(3)术前合并心脑血管疾病受者；(4)边缘供肝(包括高龄供肝、脂肪肝供肝、劈离式肝移植供肝、病毒性肝炎供肝、高钠血症供肝、血流动力学不稳定，以及术前存在潜在供者来源性感染供肝等)；(5)联合其他器官移植受者。

1.2 分组标准

按照Clavien-Dindo分级^[9]将肝移植术后并发症分为5级，仅统计3级及以上并发症。3级并发症为需要行手术、内镜或介入干预的并发症，包括血管并发症(如门静脉狭窄、门静脉血栓、肝动脉血栓、脾肾分流、脾动脉盗血综合征等)、胆道并发症(如胆漏、胆汁引流不畅、胆管狭窄)以及其他并发症(如需要行穿刺的胸腹腔积液、腹腔出血，需要放置微导管引流的T管出口漏、鼻肠管置入等)；4级并发症以单一器官或多器官衰竭为主，包括呼吸衰竭、心力衰竭、肝衰竭、肾衰竭并需要予以气管切开、体外肺膜氧合、人工肝、透析等治疗；5级并发症包括因感染性或失血性休克、重症肺炎、心力衰竭、肝衰竭、肾衰竭、颅内出血等原因导致受者死亡。随访受者术后90 d内并发症发生情况，根据是否发生3级以上并发症分为并发症组和无并发症组。

1.3 相关变量的测定与计算

1.3.1 PMTH测定与二分类变量划分

肝移植受者术前2个月内，采用美国GE Revolution 64排CT仪行腹部CT平扫或者增强CT，在CT图像上手动测量脐平面右侧腰大肌轴向和横向厚度。轴向腰大肌厚度为腰大肌在轴向视图上的最大直径，横向腰大肌厚度为在横向视图上垂直于轴向的直径(图 1)，横向腰大肌厚度/患者身高=PMTH。PMTH与性别相关，且低PMTH与肝硬化患者的病死率相关^[4]。根据男性患者术后90 d内死亡情况绘制受试者工作特征(ROC)曲线，曲线下面积(AUC)为0.699(P=0.003)，95%CI: 0.625~0.766，敏感度为0.692，特异度为0.701，根据最佳约登指数0.394，选取截点值为17.9cm/m²，以PMTH≥17.9 cm/m²为高PMTH，以PMTH＜17.9 cm/m²为低PMTH。根据女性患者术后90 d内死亡情况绘制ROC曲线，AUC为0.750(P=0.012)，95%CI: 0.621~0.853，敏感度为0.833，特异度为0.778，根据最佳约登指数0.611 1，选取截点值为14.1 cm/m²，以PMTH≥14.1 cm/m²为高PMTH，以PMTH＜14.1 cm/m²为低PMTH。因此，通过截点值将连续变量PMTH划分为二分类变量。

图 1 CT测量脐平面右侧腰大肌轴向和横向厚度

注：腰大肌横向厚度(黑色箭头)垂直于腰大肌轴向厚度(黄色箭头)。

下载: 全尺寸图片幻灯片

1.3.2 CONUT评分

采用受者术前最近一次血清白蛋白、血清总胆固醇、总淋巴细胞数检测结果计算CONUT评分，计算方法：血清白蛋白≥35.0 g/L计0分，30.0~34.9 g/L计2分，25.0~29.9 g/L计4分，＜25.0 g/L计6分；血清总胆固醇≥180 mg/dL计0分，140~179 mg/dL计1分，100~139 mg/dL计2分，＜100 mg/dL计3分；总淋巴细胞计数≥1.60×10⁹/L计0分，1.20~1.59×10⁹/L计1分，0.80~1.19×10⁹/L计2分，＜0.80×10⁹/L计3分。

1.3.3 其他相关指标

收集受者年龄、性别、体质量指数(BMI)、血型、MELD评分[MELD评分=9.57×ln血肌酐(mg/dL)+3.78×ln血清总胆红素(mg/dL)+11.2×ln国际标准化比值+6.4×病因(胆汁淤积性和酒精性肝硬化为0，其他为1)]、血清总胆红素、血肌酐、凝血酶原时间国际标准化比值(PT-INR)、血尿素氮、血红蛋白、白细胞计数、血小板计数、术中输注红细胞量、输注冰冻血浆量、失血量、无肝期、手术时间以及供体年龄、BMI、供肝冷缺血时间(cold ischemia time，CIT)和供肝热缺血时间(warm ischemia time，WIT)等资料。

1.4 伦理学审查

本研究方案经由天津市第一中心医院伦理委员会审批，批号：2019N179KY，所纳入患者均签署知情同意书。

1.5 统计学方法

采用SPSS 20.0软件进行统计学分析。数据正态性检验采用Shapiro-Wilk检验。正态分布的计量资料以x±s表示，2组间比较采用独立样本t检验。非正态分布的计量资料以M(P₂₅~P₇₅)表示，2组间比较采用Mann-Whitney U检验。计数资料2组间比较采用χ²检验或Fisher确切概率法。采用AUC以及最佳约登指数选取PMTH的截点值。单因素分析时，以P＜0.1为差异有统计学意义，将其纳入二元logistic回归，采用逐步法进行分析。采用bootstrap法(抽样1000次)进行内部验证，采用一致性指数、AUC检验模型的区分度，校正曲线及Hosmer-Lemeshow检验显示模型的拟合度，临床决策曲线检验模型的临床实用性。并发症发生率比较采用Kaplan-Meier法，以P＜0.05为差异有统计学意义。

2. 结果

2.1 一般资料

共纳入肝移植受者234例，其中并发症组97例，无并发症组137例。并发症组中，男73例，女24例，年龄(50±9)岁，原发病包括乙型肝炎肝硬化24例，自身免疫性肝硬化8例，酒精性肝硬化14例，非酒精性脂肪性肝病2例，隐源性肝硬化1例，肝癌合并肝硬化25例(合并乙型或丙型肝炎)，肝衰竭20例，其他3例；无并发症组中，男101例，女36例，年龄(49±10)岁，原发病包括乙型肝炎肝硬化43例，丙型肝炎肝硬化2例，自身免疫性肝硬化18例，酒精性肝硬化10例，非酒精性脂肪性肝病4例，隐源性肝硬化2例，肝癌合并肝硬化36例(合并乙型或丙型肝炎)，肝衰竭19例，其他3例。两组原发病分布差异比较，差异无统计学意义(P=0.403)。根据PMTH测定结果，男性患者中高PMTH 117例，低PMTH 57例；女性患者中高PMTH 43例，低PMTH 17例。

2.2 建立预测模型

2.2.1 单因素分析

并发症组患者MELD评分、低PMTH比例、血清总胆红素、血肌酐、血尿素氮、CONUT评分、术中输注红细胞量、术中输注冰冻血浆量均明显高于无并发症组，血红蛋白水平明显低于无并发症组(P值均＜0.1)。其他差异均无统计学意义(P值均＞0.1)(表 1)。

表 1 肝移植术后早期并发症危险因素单因素分析

指标	并发症组(n=97)	无并发症组(n=137)	统计值	P值
受者信息
年龄(岁)	50±9	49±10	t=0.780	0.354
性别[例(%)]			χ²=0.070	0.791
男	73(75)	101(74)
女	24(25)	36(26)
BMI (kg/m²)	24.0(21.7~27.0)	23.5(21.2~26.0)	Z=-0.944	0.345
血型不相容[例(%)]	5(5.2)	8(5.8)	χ²=0.051	1.000
MELD评分	20(16~24)	13(10~20)	Z=5.499	＜0.001
PMTH[例(%)]			χ²=14.381	＜0.001
低	44(45)	30(22)
高	53(55)	107(78)
血清总胆红素(μmol/L)	123.0(72.1~379.2)	29.9(18.0~115.6)	Z=6.792	＜0.001
血肌酐(μmol/L)	68.0(51.0~118.5)	61.0(50.0~69.5)	Z=2.371	0.018
PT-INR	1.50(1.18~2.03)	1.45(1.19~1.97)	Z=0.228	0.820
血尿素氮(mmol/L)	5.3(3.7~11.8)	4.7(3.5~5.8)	Z=2.560	0.010
血红蛋白(g/L)	100±25	107±29	t=-2.097	0.044
白细胞计数(×10⁹/L)	4.9(3.4~6.8)	4.6(3.1~6.8)	Z=0.985	0.324
血小板计数(×10⁹/L)	93(47~152)	117(54~170)	Z=-1.441	0.150
ConUT评分(分)	7(6~8)	5(3~7)	Z=6.308	0.004
手术情况
术中输注红细胞量(U)	10(8~12)	8(6~10)	Z=2.456	0.014
术中输注冰冻血浆量(mL)	2000(1600~2350)	2000(1400~2000)	Z=2.171	0.030
术中失血量(mL)	2000(1500~2450)	1800(1500~2400)	Z=1.365	0.172
无肝期(min)	45(35~50)	45(40~50)	Z=-0.051	0.959
手术时间(h)	8.0±1.6	7.8±1.5	t=1.144	0.200
供者信息
年龄(岁)	41±9	42±10	t=-0.904	0.939
BMI(kg/m²)	24.1(21.4~27.4)	23.8(22.1~26.4)	Z=-0.255	0.799
CIT(h)	7.3(6.4~7.9)	6.8(6.2~7.8)	Z=1.138	0.255
WIT(min)	5.8±1.7	5.7±1.5	t=0.237	0.182

下载: 导出CSV

| 显示表格

2.2.2 预测模型的推导与建立

二元logistc多因素分析(采用逐步法分析，由于有报道^[10]称CIT、WIT为肝移植术后胆道并发症的危险因素，遂将二者均纳入)结果显示，MELD评分、低PMTH比例、CONUT评分为肝移植术后3级及以上并发症发生的独立危险因素(P值均＜0.05) (表 2)。笔者根据Framingham研究中心提供的logistic模型建立积分系统的方法^[11]，以0.393为常量，将此常量设定为1分，设定变量CONUT评分截距为1，基于MELD评分，PMTH、血清白蛋白、血清总胆固醇以及总淋巴细胞计数建立了一个简单的肝移植术后并发症风险预测模型(表 3)，该预测模型最高分为24分。

表 2 肝移植术后早期并发症危险因素多因素分析

危险因素	β值	P值	OR	95%CI
MELD评分	0.099	0.002	1.104	1.057~1.154
PMTH	1.050	＜0.001	2.858	1.451~5.626
ConUT评分	0.393	＜0.001	1.481	1.287~1.703

下载: 导出CSV

| 显示表格

表 3 肝移植术后早期并发症风险预测模型

危险因素	得分
MELD评分
＜10分	0
10~19分	3
20~29分	6
≥30分	9
PMTH
高	0
低	3
血清白蛋白
≥35.0 g/L	0
30.0~34.9 g/L	2
25.0~29.9 g/L	4
＜25.0 g/L	6
血清总胆固醇
≥180 g/L	0
140~179 g/L	1
100~139 g/L	2
＜100 g/L	3
总淋巴细胞计数
≥1.60×10⁹/L	0
1.20×10⁹/L~1.59 ×10⁹/L	1
0.80×10⁹/L~1.19×10⁹/L	2
＜0.8×10⁹/L	3

下载: 导出CSV

| 显示表格

2.3 预测模型的内部验证与评价

运用bootstrap法(抽样1000次)对该预测模型进行内部验证，其一致性指数为0.828，95%CI: 0.826~0.829。AUC=0.812，P＜0.001(图 2)，95%CI: 0.756~0.860，敏感度为0.792，特异度为0.751，最佳约登指数为0.507，表明该预测模型具有良好的区分度。该预测模型校正曲线接近参考曲线(图 3)，Hosmer-Lemeshow检验表明该预测模型具有良好的拟合度(χ²=8.525，P=0.382)。决策曲线显示大部分患者均能从预测模型中获益，且净获益率较高(图 4)，表明该预测模型具有良好的临床实用性。

图 2 肝移植术后早期并发症风险预测模型ROC曲线

下载: 全尺寸图片幻灯片

图 3 预测模型校正曲线

注：Bootstrap法抽样1000次，平均绝对误差=0.044，n=234。

下载: 全尺寸图片幻灯片

图 4 预测模型决策曲线

下载: 全尺寸图片幻灯片

2.4 风险评分分组及并发症发生率

根据最佳约登指数，选择11分为截点值，并根据受者术后实际并发症发生情况，将风险评分进一步划分为低风险组(＜8分，n=55)，中风险组(8~10分，n=63)、高风险组(11~14分，n=67)、极高风险组(≥15分，n=49)。根据4组3级以上并发症发生率分别制作Kaplan-Meier曲线，结果显示，术后90 d，低风险组、中风险组、高风险组、极高风险组累积并发症发生率分别为3.6%、28.6%、59.7%、75.5%，并发症发生率随着风险评分的上升而递增(P＜0.001)(图 5)。

图 5 肝移植术后早期并发症发生率Kaplan-Meier曲线

下载: 全尺寸图片幻灯片

3. 讨论

近年来，肝移植技术不断完善发展，但对术后各类并发症的控制仍不理想，严重影响受者和移植肝的长期存活^[12]。据报道^[13-14]，营养状态是影响肝移植受者预后的因素之一。目前，临床常用的营养状态评估工具主要包括BMI、营养风险筛查2002(nutrition risk screening 2002，NRS2002)、皇家自由医院-营养优先排序工具(Royal Free Hospital-nutritional prioritizing tool，RFH-NPT)、上臂围、肌量和肌肉功能测定等^{[13, 15-16]}。由于部分终末期肝病患者存在大量腹腔积液，难以精确地测量其体质量，并且部分患者由于长期卧床，缺少术前体质量数据，因此，使用BMI对肝移植术前患者进行营养评估缺乏准确性。而NRS2002和RFH-NPT均需要评估一段时间内患者体质量和进食量变化^[17-18]，实际统计时往往掺杂患者的主观因素，且对于依从性较差的患者往往难以获取相关数据；此外，部分患者因为病情严重，短期内亟需行肝移植术，难以完成长期检测，影响了NRS2002、RFH-NPT的临床应用。上臂围是非常客观的营养评估指标，其不受液体潴留以及周围水肿的影响，操作方法简单、易行，有学者^[19-20]推荐其作为慢性肝病的筛查指标，但其并不是我国肝移植患者的基本检测项目，且因测量者不同，测量结果可能存在一定误差。测量全身的骨骼肌含量是诊断肌肉减少症的金标准，但是测量工作复杂、繁琐，需要通过测量第3腰椎水平面的骨骼肌指数(skeletal muscle index，SMI)并依赖相关软件实现对骨骼肌含量的计算^[21-23]。

笔者团队在设计建立肝移植术后早期并发症风险预测模型前，全面分析了数种营养相关指标，并结合临床实际，最终选定纳入CONUT评分、PMTH、血清白蛋白、总淋巴细胞计数、血清总胆固醇、MELD评分作为参数。CONUT评分的计算需要的3个指标(血清白蛋白、血清总胆固醇、总淋巴细胞计数)均与临床紧密相关，且为患者定期检查项目，容易及时获得数据，计算方法简单。而相比于需要计算第3腰椎水平面的SMI，PMTH仅需要在CT图像上测量右侧腰大肌的横向厚度，其过程方便、简洁。研究^[24]表明，在肝硬化患者中，PMTH与第3腰椎水平面的SMI高度相关，是肝硬化患者死亡的独立危险因素。腰大肌的横向厚度与性别、年龄、人种相关，因此，笔者根据本研究数据确定出截点值，即男性患者PMTH＜17.9 cm/m²诊断为低PMTH，女性患者PMTH＜14.1 cm/m²诊断为低PMTH。本研究结果显示，低PMTH受者术后3级以上并发症发生风险明显增加，究其原因可能是由于骨骼肌含量减少导致氨基酸存储降低，从而不能为细胞修复提供足量的氨基酸，进而导致血管、胆道相关并发症以及伤口不愈合^[25]；再者，骨骼肌可以释放谷氨酰胺激活淋巴细胞，从而提高机体免疫力^[26-28]，而骨骼肌减少使受者免疫力下降，同时，受者呼吸肌肌肉含量减少，一定程度上引起术后咳痰能力下降，导致肺相关并发症发生^[29]。而受者白蛋白、总淋巴细胞计数水平降低将导致机体免疫力降低，使受者术后易发肺炎、伤口感染等并发症。在终末期肝病患者中，由于肝功能受损，导致肝细胞合成胆固醇能力下降，而胆固醇是细胞膜的组成成分，发挥着维持细胞结构和功能的作用，胆固醇的减少可能会使细胞修复功能受损，导致术后相关并发症^[30]。另据报道^[10]，较长的供肝冷、热缺血时间是术后胆道并发症发生的危险因素。然而，本研究中未见其与术后早期3级以上并发症的发生存在相关性，可能是由于本中心供肝的冷、热缺血时间较短，一直处于安全的时间范围内^[31]。

本研究的局限性包括：(1)纳入的女性患者较少，在选取女性患者PMTH截点值时可能存在一定程度上的偏倚，影响结果的准确性；(2)受者PMTH值为术前2个月内，血清总胆固醇值为术前1周内，部分病情较重患者的PMTH以及血清总胆固醇会随着病情变化而改变，在一定程度上影响模型的准确性；(3)该预测模型仅完成内部验证，尚未开展外部验证，笔者希望今后可以联合各个移植中心，扩大样本量，进一步开展临床可行性验证。

综上所述，术前MELD评分、PMTH和CONUT评分是肝移植术后3级以上并发症发生的独立危险因素，本研究纳入MELD评分、PMTH、血清白蛋白、血清总胆固醇、总淋巴细胞计数作为参数，建立并验证了我国18~65岁人群中初次行原位肝移植的患者术后90 d内并发症发生的风险预测模型，该预测模型能够有效识别高风险患者，进而指导临床医师加强对高风险患者围手术期的管理。

References(32)

References

[1]	POWELL EE, WONG VW, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224. DOI: 10.1016/S0140-6736(20)32511-3.
[2]	YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20. DOI: 10.1038/nrgastro.2017.109.
[3]	SARIN SK, KUMAR M, ESLAM M, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission[J]. Lancet Gastroenterol Hepatol, 2020, 5(2): 167-228. DOI: 10.1016/S2468-1253(19)30342-5.
[4]	ESLAM M, VALENTI L, ROMEO S. Genetics and epigenetics of NAFLD and NASH: Clinical impact[J]. J Hepatol, 2018, 68(2): 268-279. DOI: 10.1016/j.jhep.2017.09.003.
[5]	ALEXANDER M, LOOMIS AK, van der LEI J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts[J]. BMC Med, 2019, 17(1): 95. DOI: 10.1186/s12916-019-1321-x.
[6]	SHEKA AC, ADEYI O, THOMPSON J, et al. Nonalcoholic steatohepatitis: a review[J]. JAMA, 2020, 323(12): 1175-1183. DOI: 10.1001/jama.2020.2298.
[7]	LIU SF, LIANG PS, WANG L, et al. Thinking and method of traditional Chinese medicine treatment of nonalcoholic fatty liver[J]. Global Tradit Chin Med, 2020, 13(6): 1047-1049. DOI: 10.3969/j.issn.1674-1749.2020.06.027. 刘素芳, 梁平书, 王璐, 等. 非酒精性脂肪肝的中医治疗思路与方法[J]. 环球中医药, 2020, 13(6): 1047-1049. DOI: 10.3969/j.issn.1674-1749.2020.06.027.
[8]	Diagnosis and Treatment Center of Hepatology of South China Alliance of TCM, National Administration of Traditional Chinese Medicine. Diagnosis and treatment scheme of Ganpi (non-alcoholic steatohepatitis)[J/CD]. Chin J Liver Dis (Electronic Edition), 2021, 13(1): 1-9. DOI: 10.3969/j.issn.1674-7380.2021.01.001. 国家中医药管理局华南区中医肝病诊疗中心联盟. 肝癖(非酒精性脂肪性肝炎)诊疗方案[J/CD]. 中国肝脏病杂志(电子版), 2021, 13(1): 1-9. DOI: 10.3969/j.issn.1674-7380.2021.01.001.
[9]	HAO WS. The conversion of the Han Dynasty's system of weights and measures and the quantity of classical prescriptions[J]. Chin Med Modern Distance Educ of China, 2005, 3(3): 48-51. DOI: 10.3969/j.issn.1672-2779.2005.03.016. 郝万山. 汉代度量衡制和经方药量的换算[J]. 中国中医药现代远程教育, 2005, 3(3): 48-51. DOI: 10.3969/j.issn.1672-2779.2005.03.016.
[10]	TONG XL, MU LC, WU YC, et al. Modern measurement and research on non-unit drug weight in the prescription of treatise on febrile diseases[J]. J Tradit Chin Med, 2009, 50(S1): 1-2. DOI: 10.13288/j.11-2166/r.2009.s1.090. 仝小林, 穆兰澄, 吴义春, 等. 《伤寒论》方剂中非计量单位药物重量的现代实测研究[J]. 中医杂志, 2009, 50(S1): 1-2. DOI: 10.13288/j.11-2166/r.2009.s1.090.
[11]	ALVAREZ CS, GRAUBARD BI, THISTLE JE, et al. Attributable fractions of nonalcoholic fatty liver disease for mortality in the United States: Results from the Third National Health and Nutrition Examination Survey with 27 years of follow-up[J]. Hepatology, 2020, 72(2): 430-440. DOI: 10.1002/hep.31040.
[12]	TILG H, TARGHER G. NAFLD-related mortality: simple hepatic steatosis is not as 'benign' as thought[J]. Gut, 2021, 70(7): 1212-1213. DOI: 10.1136/gutjnl-2020-323188.
[13]	TILG H, MOSCHEN AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis[J]. Hepatology, 2010, 52(5): 1836-1846. DOI: 10.1002/hep.24001.
[14]	TILG H, ADOLPH TE, MOSCHEN AR. Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade[J]. Hepatology, 2021, 73(2): 833-842. DOI: 10.1002/hep.31518.
[15]	HE YN, SHI JP. Research and development of new drugs for nonalcoholic steatohepatitis: An unmet need in clinical practice[J]. J Clin Hepatol, 2021, 37(6): 1241-1244. DOI: 10.3969/j.issn.1001-5256.2021.06.001. 何忆宁, 施军平. 非酒精性脂肪性肝炎新药研发: 一个未被满足的临床需求[J]. 临床肝胆病杂志, 2021, 37(6): 1241-1244. DOI: 10.3969/j.issn.1001-5256.2021.06.001.
[16]	JI G, FAN JG, CHEN JJ, et al. Clinical study on treatment of non-alcoholic fatty liver of damp-heat syndrome type by Danning tablet[J]. Chin J Integr Tradit West Med, 2005, 25(6): 485-488. DOI: 10.3321/j.issn:1003-5370.2005.06.001. 季光, 范建高, 陈建杰, 等. 胆宁片治疗非酒精性脂肪性肝病(湿热型)的临床研究[J]. 中国中西医结合杂志, 2005, 25(6): 485-488. DOI: 10.3321/j.issn:1003-5370.2005.06.001.
[17]	HUANG X, ZHANG ZY. A clinical observation on Dangfei Liganning capsule for 32 cases of nonalcoholic fatty liver disease[J]. J Tradit Chin Med, 2007, 48(6): 524-525. DOI: 10.3321/j.issn:1001-1668.2007.06.015. 黄欣, 张哲永. 当飞利肝宁胶囊治疗非酒精性脂肪性肝病32例临床观察[J]. 中医杂志, 2007, 48(6): 524-525. DOI: 10.3321/j.issn:1001-1668.2007.06.015.
[18]	YU X, WANG WJ, JIN JY, et al. Linggui Zhugan decoction combined with probiotics in the treatment of nonalcoholic fatty liver disease[J]. J Changchun Univ Chin Med, 2019, 35(5): 891-894. DOI: 10.13463/j.cnki.cczyy.2019.05.022. 喻晓, 王雯婕, 金嘉悦, 等. 苓桂术甘汤联合益生菌治疗非酒精性脂肪肝[J]. 长春中医药大学学报, 2019, 35(5): 891-894. DOI: 10.13463/j.cnki.cczyy.2019.05.022.
[19]	CUI YH. Clinical observation on treating nonalcoholic fatty liver disease with the Erchen decoction[J]. Clin J Chin Med, 2018, 10(4): 59-60. DOI: 10.3969/j.issn.1674-7860.2018.04.029. 崔玉红. 二陈汤加味治疗非酒精性脂肪肝临床疗效观察[J]. 中医临床研究, 2018, 10(4): 59-60. DOI: 10.3969/j.issn.1674-7860.2018.04.029.
[20]	LI HS, FENG Q, ZHU DD, et al. Clinical observation on Qushi Huayu decoction for 82 cases of non-alcoholic steatohepatitis with phlegm-stasis accumulation syndrome[J]. Chin Arch Tradit Chin Med, 2013, 31(8): 1764-1767. DOI: 10.13193/j.issn.1673-7717.2013.08.017. 李红山, 冯琴, 朱德东, 等. 祛湿化瘀方治疗痰瘀互结型非酒精性脂肪性肝炎临床观察[J]. 中华中医药学刊, 2013, 31(8): 1764-1767. DOI: 10.13193/j.issn.1673-7717.2013.08.017.
[21]	DING JL, FANG CY. Based on the synopsis of the golden chamber, discuss the application of classical prescriptions in the treatment of nonalcoholic fatty liver disease[J]. Jiangsu J Traditi Chin Med, 2021, 53(2): 21-23. DOI: 10.19844/j.cnki.1672-397X.2021.02.009. 丁佳璐, 方晨晔. 基于《金匮要略》探讨经方在非酒精性脂肪性肝病治疗中的应用[J]. 江苏中医药, 2021, 53(2): 21-23. DOI: 10.19844/j.cnki.1672-397X.2021.02.009.
[22]	JIANG Y. Liu Duzhou's experience in treating liver diseases[J]. Liaoning J Tradit Chin Med, 2004, 31(7): 533-534. DOI: 10.3969/j.issn.1000-1719.2004.07.002. 蒋燕. 刘渡舟治疗肝病组方用药经验[J]. 辽宁中医杂志, 2004, 31(7): 533-534. DOI: 10.3969/j.issn.1000-1719.2004.07.002.
[23]	LI H, WANG CF. Experimental study on the prevention and treatment of liver fibrosis with Xuanfuhua Kudouzi mixture[J]. Xinjiang J Tradit Chin Med, 2009, 27(1): 21-23. DOI: 10.3969/j.issn.1009-3931.2009.01.010. 李红, 王存芬. 旋覆花苦豆子合剂防治肝纤维化的实验研究[J]. 新疆中医药, 2009, 27(1): 21-23. DOI: 10.3969/j.issn.1009-3931.2009.01.010.
[24]	YANG SC, LIU SJ, ZHONG XL, et al. Experimental study on the anti-immune liver injury of Xuanfuhua Kudouzi mixture[J]. Xinjiang J Tradit Chin Med, 2008, 26(1): 7-10. DOI: 10.3969/j.issn.1009-3931.2008.01.005. 杨舒淳, 刘姝君, 钟晓玲, 等. 旋覆花苦豆子合剂应用于抗免疫性肝损伤的实验研究[J]. 新疆中医药, 2008, 26(1): 7-10. DOI: 10.3969/j.issn.1009-3931.2008.01.005.
[25]	LU X, GU HT, LU H, et al. Laboratory study on antiliver fibrosis and antisinusoid capillarization of Xuanfuhua decoction[J]. Chin J Tradit Med Sci Technol, 1999, 6(6): 366-367, 6. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYY199906009.htm 陆雄, 顾宏图, 卢红, 等. 旋复花汤对肝纤维化、肝窦毛细血管化逆转作用的实验研究[J]. 中国中医药科技, 1999, 6(6): 366-367, 6. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYY199906009.htm
[26]	ZHOU F, ZHOU J, WANG W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133. DOI: 10.1002/hep.30702.
[27]	YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
[28]	ECKARD C, COLE R, LOCKWOOD J, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial[J]. Therap Adv Gastroenterol, 2013, 6(4): 249-259. DOI: 10.1177/1756283X13484078.
[29]	PROMRAT K, KLEINER DE, NIEMEIER HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis[J]. Hepatology, 2010, 51(1): 121-129. DOI: 10.1002/hep.23276.
[30]	TAYLOR RS, TAYLOR RJ, BAYLISS S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis[J]. Gastroenterology, 2020, 158(6): 1611-1625. DOI: 10.1053/j.gastro.2020.01.043.
[31]	WANG CE, XU WT, GONG J, et al. Research progress in the treatment of nonalcoholic fatty liver disease[J]. Chin J Med Offic, 2022, 50(9): 897-899, 903. DOI: 10.16680/j.1671-3826.2022.09.06. 王彩娥, 许文涛, 宫建, 等. 非酒精性脂肪性肝病治疗研究进展[J]. 临床军医杂志, 2022, 50(9): 897-899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.
[32]	SHEN ZY, CAI XB, LU LG. Application of farnesoid X receptor agonists in treatment of nonalcoholic steatohepatitis[J]. J Clin Hepatol, 2022, 38(6): 1402-1405. DOI: 10.3969/j.issn.1001-5256.2022.06.038. 沈镇扬, 蔡晓波, 陆伦根. 法尼醇X受体激动剂在非酒精性脂肪性肝炎治疗中的应用[J]. 临床肝胆病杂志, 2022, 38(6): 1402-1405. DOI: 10.3969/j.issn.1001-5256.2022.06.038.

Relative Articles

[1]	Zhiying LIU, Zhihang ZHOU, Song HE. Research advances in the role of blood metabolic markers in the treatment response and prognosis prediction of primary liver cancer[J]. Journal of Clinical Hepatology, 2023, 39(10): 2470-2475. doi: 10.3969/j.issn.1001-5256.2023.10.028
[2]	Wang ZhiXin, Li Yao, Zhou LiuXin, Ren Li, Qu Kai, Miao Run, Hou LiChao, Wang HaiJiu, Liu Chang, Fan HaiNing. Influence of 5-hydroxytryptamine and platelet count in peripheral blood on the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1534-1539. doi: 10.3969/j.issn.1001-5256.2020.07.017
[3]	Lu Qian, Zhu Li, Cheng Xin, Huang Hua, Chen Zhong. Expression of proteasome subunit beta type 4 in hepatocellular carcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2020, 36(2): 372-376. doi: 10.3969/j.issn.1001-5256.2020.02.028
[4]	Zhang DaLi, Feng DanNi, Zhang LiJuan, Tang RuJia, He Xi, Zhou Xia, Gao YinJie, Liu ZhenWen, Liu HongLing. Risk factors for recurrence after liver transplantation in patients with hepatocellular carcinoma and their prognosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1985-1989. doi: 10.3969/j.issn.1001-5256.2020.09.015
[5]	Fu YiZhen, Xu Li. Advances in multimodality therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2179-2183. doi: 10.3969/j.issn.1001-5256.2020.10.004
[6]	Wang ZheXuan, Wang EnXin, Xia DongDong, Bai Wei, Wang QiuHe, Yuan Jie, Li XiaoMei, Niu Jing, Guo WenGang, Li Kai, Yin ZhanXin, Han GuoHong. Value of Child-Pugh score versus albumin-bilirubin grade in predicting the prognosis of unresectable hepatocellular carcinoma treated by transarterial chemoembolization[J]. Journal of Clinical Hepatology, 2020, 36(1): 113-117. doi: 10.3969/j.issn.1001-5256.2020.01.025
[7]	Zang YouYa, Long PeiYun, Han ZhiWei, Wang Huan, Ruan JingSheng, Huang Shan, Wu GuoBin, Chen Chuang. Establishment and verification of a nomogram for predicting patient prognosis after hepatectomy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(10): 2225-2230. doi: 10.3969/j.issn.1001-5256.2019.10.019
[8]	Chen Chuang, Long PeiYun, Chen Jie, Wang Pan, Huang QingYun, Zang YouYa, Deng GuoYu, Lin DongYi, Wang ZongYu. Value of Barcelona Clinic Liver Cancer staging system versus Hong Kong Liver Cancer staging system in predicting the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(3): 530-534. doi: 10.3969/j.issn.1001-5256.2019.03.016
[9]	Tang Ling, Qiu LuDie, Qin Wen, Wu Gang. Expression of circular RNA FLI1 in patients with hepatocellular carcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2019, 35(9): 1980-1984. doi: 10.3969/j.issn.1001-5256.2019.09.019
[10]	Luo Hao, Huang Jun. Clinical value of albumin-bilirubin grade in evaluating the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1608-1612. doi: 10.3969/j.issn.1001-5256.2019.07.040
[11]	He YaJing, Zhang ZhiMing, He WeiMeng, Hou JinLin. Epidemiological characteristics and prognosis of hepatocellular carcinoma: A single-center observational real-world cohort study of 1302 cases[J]. Journal of Clinical Hepatology, 2019, 35(5): 1002-1007. doi: 10.3969/j.issn.1001-5256.2019.05.014
[12]	Zhu Feng, Feng XiaoHai, An Yue. Association between the expression of somatostatin receptors and pathological features, prognosis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(2): 314-320. doi: 10.3969/j.issn.1001-5256.2018.02.019
[13]	Wen XiaJie, Yao MingJie, Zhang Ling, Lu FengMin. Value of common laboratory parameters in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(7): 1395-1398. doi: 10.3969/j.issn.1001-5256.2018.07.006
[14]	Lu DongLing, Zhu YuPing, Ou Jie, Mao SuFei, Wu GuoBin, He JianBo, Huang Shan, Chen Chuang. Clinical effects of different treatment regimens for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma and influencing factors for prognosis[J]. Journal of Clinical Hepatology, 2018, 34(9): 1905-1910. doi: 10.3969/j.issn.1001-5256.2018.09.016
[15]	Zhao Han, Chen Keng, Ying RuoSu, Li PingHong, Liu HuiYuan. Clinical features of hepatocellular carcinoma in pregnancy[J]. Journal of Clinical Hepatology, 2018, 34(8): 1693-1696. doi: 10.3969/j.issn.1001-5256.2018.08.020
[16]	Wang XianBo, Gao FangYuan, Liu Yao. Neutrophil- lymphocyte ratio: a novel predictor of clinical outcome of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(4): 649-652. doi: 10.3969/j.issn.1001-5256.2016.04.007
[17]	Zhang Cheng, Qi XingShun, Bo Ming, Zhao Yan, Wang WeiJuan, Han GuoHong. Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma complicated by portal vein tumor thrombus[J]. Journal of Clinical Hepatology, 2016, 32(1): 84-87. doi: 10.3969/j.issn.1001-5256.2016.01.014
[18]	Ma ShiJie, Zou ShaoJing, Luo XiaoLing, Li QianJun, Huang JiaSheng. Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(1): 80-83. doi: 10.3969/j.issn.1001-5256.2016.01.013
[19]	Li Peng, Zhai Yun, Zhang ShiBin, Li Lei, Ding HuiGuo. Analysis of quality of life and prognosis in patients with HBV-related end-stage hepatocellular carcinoma after antiviral therapy[J]. Journal of Clinical Hepatology, 2015, 31(5): 721-724. doi: 10.3969/j.issn.1001-5256.2015.05.021
[20]	Jia Jia, Qi XingShun, Han GuoHong. Prognostic value of α-fetoprotein response in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2013, 29(8): 576-580. doi: 10.3969/j.issn.1001-5256.2013.08.006

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	李正优，李荷，周俊. 预见性护理结合舒适护理干预在肝移植术后患者中的应用. 西藏医药. 2024(06): 123-125 .
2.	李珊珊，王媛，高春辉. 早期下床活动对肝移植术后患者胃肠功能及下肢血流的影响. 国际移植与血液净化杂志. 2023(01): 41-44 .
3.	张欣悦，王海刚，王昊，杨传伟. 他克莫司治疗1例肝移植术后患者的药学监护. 中国医药导报. 2023(14): 183-187 .
4.	种庚，彭晓春，吴若林，赵红川，邵敏. 成人肝移植术后早期严重并发症相关危险因素分析. 肝胆外科杂志. 2022(06): 454-459 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4) / Tables(8)

Get Citation

PDF

XML

Article Metrics

Article views (623) PDF downloads(45)

Effect of Xuanfuhua decoction on a mouse model of nonalcoholic steatohepatitis induced by high-fat, high-fructose, and high-cholesterol diet

DOI: 10.3969/j.issn.1001-5256.2023.06.014